Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
184.84
+4.02 (2.22%)
At close: Sep 26, 2025, 4:00 PM EDT
185.35
+0.51 (0.28%)
After-hours: Sep 26, 2025, 7:48 PM EDT
Danaher Revenue
Danaher had revenue of $5.94B in the quarter ending June 27, 2025, with 3.36% growth. This brings the company's revenue in the last twelve months to $24.01B, up 1.89% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$24.01B
Revenue Growth
+1.89%
P/S Ratio
5.54
Revenue / Employee
$381,159
Employees
63,000
Market Cap
132.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DHR News
- 1 day ago - Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR - PRNewsWire
- 4 days ago - Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR - GlobeNewsWire
- 4 days ago - Danaher Schedules Third Quarter 2025 Earnings Conference Call - PRNewsWire
- 16 days ago - Analysts' Top S&P 500 Stocks to Buy Now - Kiplinger
- 17 days ago - Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research - PRNewsWire
- 18 days ago - Danaher Announces Quarterly Dividend - PRNewsWire
- 22 days ago - DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR - PRNewsWire
- 4 weeks ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha